Attendee search 

Theravance, Inc. - Medicines that Make A Difference®

Summary Products / Services / Technologies

Collaborations and Clients

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticalshas entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found athttp://www.mappharma.com.

NanoSmart has developed and patented, a targeted drug delivery platform using human-derived, autoimmune antibodies capable of targeting many different kinds of tumors.  NanoSmart’s antitumor antibody, is not tumor-marker specific, but rather targets the areas of necrosis present in all solid tumors; including breast, lung, prostate, and rare cancers like Ewing’s Sarcoma.  Normal tissues do not have areas of necrosis and are not targeted.

NanoSmart is encapsulating off-patent FDA-approved drugs within liposomes coated with NanoSmart’s human-derived antibodies, thus creating an immunoliposome.  The liposome that encloses the active pharmaceutical ingredient protects healthy tissues while traveling to its target, and then slowly releases the drug over time.  NanoSmart’s antibody will then bind to the necrotic areas present in the middle of solid tumors and at the surrounding tumor site.

The end-result of using NanoSmart’s platform is a superior safety and efficacy profile for any drug that is adapted to our system.  Many different formulations can be developed by simply replacing one drug with another.  Each formulation is novel, patentable, and non-tumor specific (i.e. targets multiple cancers), and can be developed at a fraction of the cost and time typically associated with new drug development (i.e. IND to NDA in approximately 2-3 years).

MannKind’s patient-focused oral inhalation drug delivery technologies include a dry powder formulation capability coupled with an innovative, elegant, breath-powered delivery device. We are applying these technologies to facilitate partnered drug development programs for proprietary compounds.

MannKind has numerous collaborations across therapeutic areas that demonstrate the efficacy and safety of the technologies. Patients self-administer these dry powder formulations with small, easy-to-use, breath-powered inhalers. Following inhalation, drugs are absorbed very rapidly, essentially mimicking intra-arterial administration. MannKind has evaluated this versatile pulmonary drug delivery platform across multiple therapeutic areas, including diabetes, metabolism, respiratory disease, osteoporosis and pain.

For companies interested in exploring the feasibility of a Technosphere formulation using their own active pharmaceutical ingredient (API), MannKind offers a feasibility evaluation. These evaluations involve preparation and characterization of API/Technosphere formulations. These powders are tested for performance in MannKind’s inhalers. Additionally, MannKind works with the partner to test these powders in relevant nonclinical PK/PD models. These studies can often been completed within 6 months. 

MannKind seeks to establish partnerships to build therapeutic programs of significant clinical and commercial value. Whether through strategic alliances, licensing arrangements and/or research collaborations, MannKind's partnering approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

Relay brings you BD Live! – a software solution providing business intelligence to life science professionals to validate opportunities, discover new assets, and assess their pipelines against their competitors. BD Live! provides real-time trend monitoring and comparative asset analysis and complements existing evaluation models to help business development professionals hone in on promising new technologies and avoid transactions that have limited potential.